In April 2008, certolizumab pegol (Cimzia; UCB), a tumour-necrosis factor blocker, was approved by the US FDA for the treatment of adult patients with moderate-to-severe Crohn's disease who have ...

Thus there has been the development of a number of other biologic agents for use in RA including the new TNFi agents: certolizumab pegol (CZP) and golimumab. Experience [5] and randomized ...

for Conditional Approval of avacincaptad pegol intravitreal solution (ACP), a synthetic aptamer that inhibits the complement C5 protein, for the treatment of GA secondary to AMD. If approved ...